- General Aspects of Neuroscience Drug Discovery and Development
-
55 min
-
33 min
- Seizure Disorders
-
35 min
-
47 min
- Alzheimer's Disease
-
54 min
-
28 min
-
68 min
-
19 min
-
23 min
- Parkinson's Disease
-
51 min
- Schizophrenia
-
20 min
-
33 min
Topics Covered
- The Australian imaging, biomarkers and lifestyle (aibl) flagship study of ageing
- Methodology: key outcomes
- Abeta and amyloid imaging
- The progression of AD
- Abeta and memory
- Prediction of conversion from HC to MCI/AD
- Impact of amyloid imaging in MCI patient selection for anti-amyloid therapeutic trials
- Longitudinal PiB PET follow-up
- Plasma Abeta 42 levels in the PiB-PET AIBL subset
- Relation between Abeta oligomers in blood cellular elements, cognition and PiB SUVR
- Plasma ApoE (total) levels: the AIBL study
- Biomarker discovery
- Abeta deposition
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Masters, C.L. (2011, October 27). Abeta toxicity 2 [Video file]. In
The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved July 2, 2022, from
https://hstalks.com/bs/2132/.
Publication History
-
Published on October 27, 2011
Financial Disclosures
- Prof. Colin L. Masters has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.